These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20218855)

  • 1. World Influenza Congress Europe 2009.
    Silman NJ
    Expert Rev Vaccines; 2010 Mar; 9(3):273-5. PubMed ID: 20218855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terrapinn's world influenza congress Europe 2009. Part 1.
    Veryard C
    IDrugs; 2010 Feb; 13(2):76-7. PubMed ID: 20127555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.
    Hasegawa H; Ichinohe T; Tamura S; Kurata T
    Expert Rev Vaccines; 2007 Apr; 6(2):193-201. PubMed ID: 17408369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influenza A/H5N1 virus outbreaks and prepardness to avert flu pandemic].
    Haque A; Lucas B; Hober D
    Ann Biol Clin (Paris); 2007; 65(2):125-33. PubMed ID: 17353166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing cell culture-derived pandemic vaccines.
    Barrett PN; Portsmouth D; Ehrlich HJ
    Curr Opin Mol Ther; 2010 Feb; 12(1):21-30. PubMed ID: 20140813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Avian influenza vaccines].
    Vasil'ev IuM
    Vopr Virusol; 2008; 53(6):4-15. PubMed ID: 19172900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seasonal, avian, and novel H1N1 influenza: prevention and treatment modalities.
    Sym D; Patel PN; El-Chaar GM
    Ann Pharmacother; 2009 Dec; 43(12):2001-11. PubMed ID: 19920156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress on baculovirus-derived influenza vaccines.
    Cox MM
    Curr Opin Mol Ther; 2008 Feb; 10(1):56-61. PubMed ID: 18228182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avian and pandemic influenza: an overview.
    Poland GA; Jacobson RM; Targonski PV
    Vaccine; 2007 Apr; 25(16):3057-61. PubMed ID: 17289227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Swine influenza virus: zoonotic potential and vaccination strategies for the control of avian and swine influenzas.
    Thacker E; Janke B
    J Infect Dis; 2008 Feb; 197 Suppl 1():S19-24. PubMed ID: 18269323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008.
    Girard M; Palkonyay L; Kieny MP
    Vaccine; 2008 Sep; 26(39):4975-7. PubMed ID: 18514979
    [No Abstract]   [Full Text] [Related]  

  • 18. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines in development against avian influenza.
    Cox MM
    Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fast track influenza virus vaccine produced in insect cells.
    Cox MM; Hashimoto Y
    J Invertebr Pathol; 2011 Jul; 107 Suppl():S31-41. PubMed ID: 21784229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.